BioSpace News Archive

BIOREM Inc. (TSXV: BRM) (“Biorem” or “the Company”) today announced its results for the three and twelve-month periods ended December 31, 2021.

IDEX CORPORATION announced that it has scheduled the broadcast of the company’s first quarter earnings conference call over the Internet on Wednesday, April 27, 2022 at 9:30 a.m. CT.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare on March 28, 2022.

AmerisourceBergen Corporation announced that it plans to release its results for the Second Quarter of Fiscal 2022 on Wednesday, May 4, 2022, prior to the opening of trading on the New York Stock Exchange.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today provided a business update for the company and presented preliminary financial results for the year ended December 2021.

Mercury Medical Has Selected Andau Medical As Their Canadian Airtraq Video Laryngoscope System Distribution Partner With the Signing of an Exclusive Agreement

Everest Medicines announced its financial results for full year ended December 31, 2021, along with a corporate progress update.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2 mg dose of Ozempic® (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.

CANbridge Pharmaceuticals Inc. announced that the Taiwan Food and Drug Administration has accepted the New Drug Application/Orphan Drug Registration for CAN108 ) for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Innovent Biologics, Inc. announced the first patient dosing for its proprietary recombinant bispecific antibody targeting Claudin18.2 and CD3 in a Phase I clinical trial for the treatment of advanced malignancies.